30 completed, 7 unknown, 3 terminated, 2 recruiting. 15 Phase 1, 11 Phase 3, 9 Phase 2, 4 Not applicable, 4 Phase 4.
Follow Edaravone: new trials by email Literature Review of Edaravone trials Research Report on Edaravone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT) Intravenous thrombolysis + edaravone, IV thrombolysis + placebo (control group) - Ischemic Stroke | Phase 4 | Recruiting | Ruijun Ji | 300 | 2024-08-01 | 2025-08-12 |
| Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects TTYP01, Radicava, Radicava ORS - Healthy Adult Subjects | Phase 1 | Completed | Shanghai Auzone Biological Technology Co., Ltd. | 29 | 2023-11-07 | 2026-04-24 |
| ASURE: Alzheimer Study Using oRal Edaravone TW001, Placebo - Alzheimer Disease | Phase 2 | Completed | Treeway B.V. | 61 | 2023-03-01 | 2025-04-23 |
| Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS MT-1186 - ALS | Phase 3 | Completed | Shionogi | 15 | 2022-10-26 | 2026-07-21 |
| Edaravone in the Treatment of Optic Neuritis Edaravone - Optic Neuritis | Not applicable | Recruiting | First Affiliated Hospital of Guangxi Medical University | 50 | 2022-01-15 | 2025-02-27 |
| Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS MT-1186, Placebo - ALS | Phase 3 | Terminated | Shionogi | 202 | 2022-01-11 | 2026-10-21 |
| Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke Compound Edaravone Injection-Low dose, Compound Edaravone Injection-High dose, Edaravone Injection - Acute Ischemic Stroke | Phase 2 | Suspended | Nanjing Yoko Biomedical Co., Ltd. | 240 | 2021-11-15 | 2024-02-20 |
| Protective Effects of Edaravone Dexborneol edaravone dexborneol or edaravone - Acute Ischemic Stroke | Not applicable | Unknown | Lili Cao | 80 | 2021-04-01 | 2021-09-13 |
| Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube MT-1186 - Healthy Adult Subjects | Phase 1 | Completed | Shionogi | 36 | 2021-02-26 | 2026-07-15 |
| Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS MT-1186, Placebo - ALS | Phase 3 | Terminated | Shionogi | 384 | 2020-11-13 | 2026-07-20 |
| The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS Scopolamine, atropine, edaravone and dexmedetomidine, Edaravone - Amyotrophic Lateral Sclerosis, Respiratory Function | Phase 2 | Unknown | Ruijin Hospital | 30 | 2020-11-01 | 2020-10-14 |
| Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) MT-1186 - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Completed | Shionogi | 124 | 2020-10-29 | 2026-07-20 |
| A Study of TTYP01 in Healthy Adult Subjects TTYP01 single ascending doses, Placebo, TTYP01, 60 mg - Healthy Adult Subjects | Phase 1 | Completed | Shanghai Auzone Biological Technology Co., Ltd. | 72 | 2020-04-24 | 2025-01-06 |
| Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy MT-1186 - Japanese Patients With ALS | Phase 1 | Completed | Shionogi | 6 | 2020-01-24 | 2026-07-16 |
| Safety Study of Oral Edaravone Administered in Subjects With ALS MT-1186 - ALS | Phase 3 | Completed | Shionogi | 185 | 2019-11-18 | 2026-07-21 |
| Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) Edaravone (Radicava®/Radicava ORS®) - Amyotrophic Lateral Sclerosis, ALS | Completed | Shionogi | 74 | 2019-10-21 | 2026-06-30 | |
| Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury Nerve Growth Factor, Edaravone, Combination of vitamin B1, B6, C, E and mecobalamine - Alcohol-induced Brain Injury | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 150 | 2019-06-30 | 2020-10-27 |
| Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study) MT-1186 - Healthy Adult Subjects | Phase 1 | Completed | Shionogi | 16 | 2019-06-10 | 2026-07-15 |
| Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection Compound Edaravone Injection, Edaravone Injection, 2-Aminoethanesulfonic Acid Injection - Drug-drug Interaction | Phase 1 | Completed | Nanjing Yoko Biomedical Co., Ltd. | 24 | 2019-05-10 | 2021-03-22 |
| Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis MT-1186 - Japanese Patients With ALS | Phase 1 | Completed | Shionogi | 9 | 2019-04-17 | 2026-07-15 |
Showing 20 of 43. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (8) · Ischemic Stroke (8) · Stroke (2) · Acute Lung Injury (1) · Alzheimer Disease (1) · Aortic Dissection (1) · Atrophy (1) · Cerebral Infarction (1) · Demyelinating Diseases (1) · Motor Neuron Disease (1) · Myocardial Infarction (1) · Nasopharyngeal Carcinoma (1) · Neuromuscular Diseases (1) · Optic Neuritis (1) · Renal Insufficiency (1)
Shionogi (24) · Jiangsu Simcere Pharmaceutical Co., Ltd. (2) · Nanjing Yoko Biomedical Co., Ltd. (2) · Shanghai Auzone Biological Technology Co., Ltd. (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Beijing Anzhen Hospital (1) · Combination Therapy for Acute Ischemic Stroke Study Group (1) · First Affiliated Hospital of Guangxi Medical University (1) · Isfahan University of Medical Sciences (1) · Kumamoto University (1) · Lili Cao (1) · Ruijin Hospital (1) · Ruijun Ji (1) · Treeway B.V. (1) · Xijing Hospital (1)
Japan (20) · China (11) · United States (6) · Canada (5) · Germany (4) · Italy (3) · France (2) · Netherlands (2) · South Korea (2) · Switzerland (2) · Australia (1) · Croatia (1) · Czechia (1) · Finland (1) · Hungary (1)
Yongjun Wang, MD (2) · Hisao Ogawa, MD, PhD (1) · James Berry, MD, MPH (1) · Jun Liu, Professor (1) · Qiang Wang (1) · Robert. Bass, MD (1) · Sepehr Shakib, MD (1) · Takenori Yamaguchi, MD, PhD (1) · WeiPing Cheng, master (1) · Yaguo Li, master (1) · Yamei Tang, M.D.,PhD. (1) · Yu-Qing Fang, MD (1) · Yumiao Zhou, master (1)
PMID 36376130, PMID 32800532, PMID 33704925, PMID 37953075, PMID 19321945, PMID 22633681, PMID 24135530, PMID 25142813, PMID 25286015, PMID 27759648, PMID 28522181, PMID 28872913, PMID 28872914, PMID 28872915, PMID 28872918, PMID 28872920, PMID 30174890, PMID 31179061, PMID 31709115, PMID 32543120, PMID 32868037, PMID 33588596, PMID 33955162, PMID 34476128, PMID 36225132, PMID 36504406, PMID 37525592, PMID 38011420, PMID 38049955, PMID 40474686, PMID 40485494, PMID 40878665
2018 (1), 2019 (1)